Antithrombotic coating material is indispensable for the production of blood-contacting medical devices. Physical coatings of inexpensive synthetic polymers are desirable to reduce medical expenses and provide patients with an opportunity to receive medical care. Poly(2-methoxyethyl acrylate) (PMEA) homopolymers are widely diffused coating materials that almost meet these requirements. However, the PMEA homopolymer coating has room for improvement because its poor coating properties cause dewetting, thus limiting the available substrates. Herein, we fabricated an inorganic/organic hybrid material using silsesquioxane (SQ) and poly(2-methoxyethyl acrylate) (PMEA) called the SQ/PMEA hybrid to overcome the limitations of existing PMEA homopolymer coatings. The SQ/PMEA hybrid was successfully synthesized by thiol-initiated radical polymerization of 2-methoxyethyl acrylate (MEA) from thiol group-containing random-type silsesquioxane (SQ-SH) utilizing 2,2′-azobis(isobutyronitrile) as a thermal initiator. This polymerization strategy readily afforded the required hybrid with various Si contents by merely changing the feed composition of the monomer and SQ-SH without a complicated procedure. The SQ/PMEA hybrid showed the formation of intermediate water essential for biocompatibility in any polymer composition. By optimizing the Si content, the hybrid formed a smooth and stable coating layer on surfaces of polymers, ceramics, and metals compared with the PMEA homopolymer even under wet conditions and significantly suppressed human platelet adhesion. In addition, the hybrid coating not only exhibited antithrombotic properties but also drastically promoted the adhesion and extension of human umbilical vein endothelial cells (HUVECs). These characteristics of the hybrid material are attractive for the surface treatment of blood-contacting devices used for a long time, including extracorporeal membrane oxygenation (ECMO) devices, blood vessels, and stents. This strategy has potential in the advancement of the biomedical fields such as tissue engineering, regenerative medicine, and minimally invasive medicine.

中文翻译：

---

具有倍增抗血栓性和内皮细胞粘附特性的倍半硅氧烷/聚（丙烯酸2-甲氧基乙酯）杂化物

抗血栓涂层材料是生产血液接触型医疗设备必不可少的。需要廉价的合成聚合物的物理涂层以减少医疗费用并为患者提供接受医疗的机会。聚（丙烯酸2-甲氧基乙基酯）（PMEA）均聚物是广泛分散的涂料，几乎可以满足这些要求。但是，PMEA均聚物涂料有改进的余地，因为其不良的涂料性能会导致脱湿，从而限制了可用的基材。在本文中，我们使用倍半硅氧烷（SQ）和聚（2-丙烯酸甲氧基乙酯）（PMEA）的倍半硅氧烷（PQ）制备了无机/有机杂化材料，以克服现有PMEA均聚物涂层的局限性。以2,2'-偶氮二（异丁腈）为热引发剂，由含硫醇基的无规倍半硅氧烷（SQ-SH）通过硫醇引发的丙烯酸2-甲氧基乙酯（MEA）的自由基聚合成功合成了SQ / PMEA杂化物。 。通过仅改变单体和SQ-SH的进料组成而无需复杂的程序，该聚合策略容易地提供了具有各种Si含量的所需杂化。SQ / PMEA杂化物显示出在任何聚合物组合物中生物相容性必不可少的中间水的形成。通过优化Si含量，与PMEA均聚物相比，该杂化物即使在潮湿条件下也能在聚合物，陶瓷和金属表面上形成光滑稳定的涂层，并显着抑制了人体血小板粘附。此外，这种杂化涂层不仅具有抗血栓形成的特性，而且还极大地促进了人脐静脉内皮细胞（HUVEC）的粘附和扩展。杂化材料的这些特性对于长时间使用的血液接触装置的表面处理具有吸引力，这些装置包括体外膜氧合（ECMO）装置，血管和支架。该策略在诸如组织工程，再生医学和微创医学等生物医学领域的发展中具有潜力。包括体外膜氧合作用（ECMO）装置，血管和支架。该策略在诸如组织工程，再生医学和微创医学等生物医学领域的发展中具有潜力。包括体外膜氧合作用（ECMO）设备，血管和支架。该策略在诸如组织工程，再生医学和微创医学等生物医学领域的发展中具有潜力。